8-K - PharmaCyte Biotech, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

PharmaCyte Biotech, Inc. obtained shareholder approval at its March 30, 2026 Annual Meeting to amend its 2022 Equity Incentive Plan by adding 2,000,000 shares and to authorize a reverse stock split of up to 1-for-100, alongside electing five directors and ratifying its auditor.

Key Takeaways

1Shareholders approved a 2,000,000-share increase to the 2022 Equity Incentive Plan, raising total authorized shares to 7,000,000 — expanding dilution potential and equity compensation capacity.

2A reverse stock split authorization (1-for-1.1 to 1-for-100) was approved, granting the Board discretion to implement it without further shareholder vote — signaling possible future compliance or market eligibility actions.

3Five directors were elected, all receiving majority 'For' votes, though each faced significant 'Withheld' votes (372,794–550,006), indicating notable dissent among participating shareholders.

4CBIZ CPAs P.C. was ratified as independent auditor with 6.84M 'For' votes, but 514,469 'Against' votes reflect meaningful auditor skepticism despite broker non-votes dominating the tally.

Current Report Details

Event Type

Management Change

Shareholder Vote

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** On March 30

Management Change

5.07

Submission of Matters to a Vote of Security Holders. ** At the Annual Meeting, 7,387,861 shares of voting stock, or approximately 55.08% of the outstanding shar

Shareholder Vote

9.01

Financial Statements and Exhibits.** (d) Exhibits. The following exhibits are filed as part of this report: | Exhibit Number | | Description | |---|---|---| | 1

Exhibits Only

Exhibits (2)

10.1

2022 INCENTIVE STOCK PLAN, AS AMENDED

8-K

FORM 8-K